Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company has an anti-infective portfolio that includes several key candidates: Favipiravir, aimed at addressing pandemic influenza and COVID-19; ATI-2307, an antifungal agent in clinical development for cryptococcal meningitis and invasive candidiasis; and ATI-1501, an oral liquid formulation of metronidazole. Additionally, Appili is advancing ATI-1503, which targets gram-negative bacteria, and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. The company seeks to address unmet medical needs through improved therapies and the development of new classes of anti-infectives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.